deltatrials
Terminated PHASE2 NCT00453973

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)

An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease

Sponsor: Affymax

Conditions Anemia Chronic Kidney Disease Chronic Renal Failure
Interventions peginesatide
Updated 8 times since 2017 Last updated: Jun 22, 2012 Started: Nov 30, 2006 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

A PHASE2 clinical study on Anemia and Chronic Kidney Disease, this trial is terminated or withdrawn. The trial is conducted by Affymax and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affymax
Data source: Affymax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arad, Romania, Bacau, Romania, Bialystok, Poland, Bucharest, Romania, Burgas, Bulgaria, Croydon, United Kingdom, Derby, United Kingdom, Iași, Romania, Katowice, Poland, Lodz, Poland and 8 more location s